Altered N-glycosylation of PD-L1 was reported to affect its activity by influencing its stability, subcellular localization, and interaction with PD-1, potentially modulating immune checkpoint signaling and impacting anti-tumor immunity (33). The gene discussed is CD274; the disease is neoplasm.